China Clinical Trials Survey Report, January 2016

Due to its large and growing pharmaceutical market, China is presumed to be a popular location for trials. This joint Applied Clinical Trials and SCORR Marketing report explores the impact of recent Chinese regulatory changes have had on trials, specifically the Nine Prohibitions, intended to combat corruption, and the Administrative Measures for Clinical Study Projects at Medical Institutions, put into place to better align procedures to good clinical practices.

*indicates a required field

lorem ipsum